Jext (Epinephrine Bitartrate)

Epinephrine is a non‑selective adrenergic agonist. By stimulating alpha‑1 receptors it causes vasoconstriction, raising systemic vascular resistance. Activation of beta‑1 receptors increases heart rate and contractility, while beta‑2 stimulation relaxes bronchial smooth muscle and limits mediator release from mast cells, together counteracting anaphylactic physiology.

The dose of Jext is determined by the prescribing clinician based on the patient’s age, weight, severity of the reaction, and clinical guidelines. No fixed regimen is provided here; the healthcare professional sets the appropriate amount and administration frequency.

Safety data for epinephrine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is reserved for situations where the benefit to the mother outweighs potential risks to the fetus or infant, and only under medical supervision.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Jext delivers epinephrine, the first‑line therapy for anaphylaxis, similar to other epinephrine autoinjectors such as EpiPen. All provide rapid intramuscular delivery; differences lie in device design, packaging, and regulatory approvals. Clinical efficacy is comparable when administered promptly at the recommended dose.

Jext should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme temperatures. Do not freeze the product, and keep it out of reach of children to maintain potency and safety.

Jext is given as an intramuscular injection, typically into the anterolateral thigh (vastus lateralis). The device is designed for rapid self‑administration; the needle is inserted through the skin and pressed firmly until the dose is delivered, after which emergency medical care should be sought.

Serious risks include cardiac arrhythmias, severe hypertension, myocardial ischemia, pulmonary edema, and tissue necrosis at the injection site. These events are rare but require immediate medical attention. Monitoring of cardiovascular status after administration is essential, especially in patients with pre‑existing heart disease.

Jext is contraindicated in patients with known hypersensitivity to epinephrine or any excipients in the formulation. Caution is advised for individuals with uncontrolled hypertension, certain cardiac disorders, pheochromocytoma, or those taking non‑selective beta‑blockers, as the drug may exacerbate these conditions.